Novartis's Entresto Clears NICE But It’s a Close Run Thing
The innovative nature of Novartis's new chronic heart failure therapy Entresto counted towards NICE's appraisal committee clearing its use in Britain's National Health Service, despite a cost-effectiveness ratio that was close to the upper limit for gaining a positive recommendation.
You may also be interested in...
Novartis AG's newly launched heart failure drug Entresto (valsartan/sacubitril), which has been dubbed the company's next blockbuster product, missed the mark in the first quarter of the year, posting sales more than $10m below analyst forecasts.
Swedish Orphan Biovitrum AB (Sobi) is preparing to respond to an "added benefit not proven" decision on its long-acting recombinant Factor VIII product Elocta (efmoroctocog) from Germany's HTA body, IQWiG, a negative ruling that the company was expecting. The response will be submitted by April 22, just before a scheduled oral meeting with IQWiG in May, with a final decision by the top HTA body, the Federal Joint Committee (G-BA), expected later this year.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.